TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06311214: Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)

Sponsor: National Cancer Institute (NCI) · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 500 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$7,438,200

Rescue Site Savings

+$4,897,200

Unlock Full NCT06311214 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06311214 Rescue Dossier →